tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders StocksMarket MoversTipRanks 50 IndexAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by UpsideTop ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Research Tools
Trending StocksCompare StocksCompare ETFsTrump Dashboard
New
Daily Feeds
Daily Analyst RatingsDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Class Actions
Stock ScreenerETF Screener
Popular
Penny Stock ScreenerTechnical Analysis Screener
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Trending News
More News >
Education
Personal FinanceHow To Use TipRanksTipRanks LabsGlossaryFAQs
About Us
About TipRanksContact UsCareersReviewsMobile APP
Working with TipRanks
Enterprise SolutionsAdvertise with UsTop Online BrokersBecome an AffiliateTipRanks News Wire
Follow Us
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders Stocks
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Trump Dashboard
New
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Advertisement
Advertisement

CLDX Stock Latest News

Celldex’s barzo shows strong efficacy in CSU patients, says H.C. Wainwright
The FlyCelldex’s barzo shows strong efficacy in CSU patients, says H.C. Wainwright
10d ago
CLDX
Celldex’s Barzolvolimab Shows Promising Efficacy in Treating Chronic Spontaneous Urticaria Across Patient Subgroups
PremiumRatings
Celldex’s Barzolvolimab Shows Promising Efficacy in Treating Chronic Spontaneous Urticaria Across Patient Subgroups
10d ago
CLDX
Celldex announces new barzolvolimab data at EADV congress
PremiumThe Fly
Celldex announces new barzolvolimab data at EADV congress
10d ago
CLDX
Celldex Therapeutics Advances in Prurigo Nodularis Treatment with Barzolvolimab Study
PremiumCompany Announcements
Celldex Therapeutics Advances in Prurigo Nodularis Treatment with Barzolvolimab Study
20d ago
CLDX
Celldex’s Phase 3 Study on Barzolvolimab: A Potential Game-Changer for Chronic Urticaria
PremiumCompany Announcements
Celldex’s Phase 3 Study on Barzolvolimab: A Potential Game-Changer for Chronic Urticaria
29d ago
CLDX
Celldex Therapeutics Advances Phase 3 Trial for Chronic Spontaneous Urticaria Treatment
PremiumCompany AnnouncementsCelldex Therapeutics Advances Phase 3 Trial for Chronic Spontaneous Urticaria Treatment
1M ago
CLDX
3 Best Stocks to Buy Now, 8/25/2025, According to Top Analysts
Premium
Market News
3 Best Stocks to Buy Now, 8/25/2025, According to Top Analysts
1M ago
BHVN
CLDX
Celldex’s Barzolvolimab: Promising Safety Profile Supports Buy Rating Despite EoE Trial Setback
Premium
Ratings
Celldex’s Barzolvolimab: Promising Safety Profile Supports Buy Rating Despite EoE Trial Setback
1M ago
CLDX
Celldex data supports positive Eupraxia thesis, says H.C. Wainwright
PremiumThe Fly
Celldex data supports positive Eupraxia thesis, says H.C. Wainwright
1M ago
CLDX
EPRX
Celldex price target lowered to $62 from $64 at Canaccord
PremiumThe Fly
Celldex price target lowered to $62 from $64 at Canaccord
1M ago
CLDX
Strategic Shift and Promising Developments Justify Buy Rating for Celldex
PremiumRatings
Strategic Shift and Promising Developments Justify Buy Rating for Celldex
1M ago
CLDX
Celldex price target lowered to $48 from $56 at Citi
PremiumThe Fly
Celldex price target lowered to $48 from $56 at Citi
1M ago
CLDX
Celldex price target lowered to $42 from $50 at H.C. Wainwright
PremiumThe FlyCelldex price target lowered to $42 from $50 at H.C. Wainwright
1M ago
CLDX
Celldex price target lowered to $38 from $44 at Wells Fargo
Premium
The Fly
Celldex price target lowered to $38 from $44 at Wells Fargo
1M ago
CLDX
Celldex’s Promising Pipeline and Financial Stability Justify Buy Rating Despite Recent Setback
Premium
Ratings
Celldex’s Promising Pipeline and Financial Stability Justify Buy Rating Despite Recent Setback
1M ago
CLDX
Closing Bell Movers: La-Z-Boy down 24% after earnings miss
PremiumThe Fly
Closing Bell Movers: La-Z-Boy down 24% after earnings miss
1M ago
ALC
JHX
Celldex down 12.5% at $21.01 after barzolvolimab study update
PremiumThe Fly
Celldex down 12.5% at $21.01 after barzolvolimab study update
1M ago
CLDX
Celldex Halts Barzolvolimab Development for EoE
PremiumCompany Announcements
Celldex Halts Barzolvolimab Development for EoE
1M ago
8K
CLDX
Celldex says barzolvolimab study meets primary endpoint, will not advance in EoE
PremiumThe Fly
Celldex says barzolvolimab study meets primary endpoint, will not advance in EoE
1M ago
CLDX
Celldex’s Barzolvolimab: A Promising EoE Treatment with Significant Market Potential – Buy Rating Justified
PremiumRatingsCelldex’s Barzolvolimab: A Promising EoE Treatment with Significant Market Potential – Buy Rating Justified
1M ago
CLDX
Celldex Therapeutics Reports Increased R&D Expenses Amid Wider Losses
Premium
Company Announcements
Celldex Therapeutics Reports Increased R&D Expenses Amid Wider Losses
1M ago
CLDX
Celldex’s Phase 3 Study on Barzolvolimab: A Potential Game-Changer for Chronic Spontaneous Urticaria
Premium
Company Announcements
Celldex’s Phase 3 Study on Barzolvolimab: A Potential Game-Changer for Chronic Spontaneous Urticaria
1M ago
CLDX

Trending

Name
Price
Price Change
SPX
S&P 500
DJIA
Dow Jones
NDX
Nasdaq 100
More Trending Stocks >